The aim of this study is to investigate whether atrial natriuretic peptide can mimic
preconditioning to protect ischemia or reperfusion injury in rabbit hearts. New Zealand white …

OBJECTIVE: Human atrial natriuretic peptide has recently become known not only as a
heart failure drug but also for myocardial protection. We investigated its direct myocardial …

BACKGROUND: Atrial natriuretic peptide (ANP), a stimulator of particulate guanylate
cyclase, has been found to protect against reoxygenation-induced hypercontracture in …

Background It has been noted that nitric oxide (NO) is involved in the ischemic
preconditioning (IPC)–mediated cardioprotection. Diabetes is a downregulator of atrial …

We investigated whether atrial natriuretic peptide (ANP) given just prior to reperfusion
reduces infarction in rabbit hearts and whether protection is related to activation of protein …

Objectives Alpha-human atrial natriuretic peptide (alpha-hANP) has been used to treat
patients with heart failure due to its natriuretic and vasodilatory activities. Recent reports …

The aim of the present study was to examine the effects of atrial natriuretic peptide (ANP) on
the responses to coronary artery occlusion. In chloralose-urethane anaesthetised mongrel …

Aim The aim of this study was to determine whether a natriuretic peptide infusion during
reperfusion can reduce cardiomyocyte ischemia–reperfusion damage. Materials and …

Plasma atrial natriuretic peptide (ANP) levels were measured in rabbits during the late
healing phase of myocardial infarcts. Significant differences in plasma ANP levels (P< 0.02) …

To evaluate the effects of synthetic human atrial natriuretic peptide (hANP) on myocardial
reperfusion injury and left ventricular remodeling, 19 patients within 12h of a first attack of …